---
title: "VIRX.US (VIRX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/VIRX.US/news.md"
symbol: "VIRX.US"
name: "VIRX.US"
parent: "https://longbridge.com/en/quote/VIRX.US.md"
datetime: "2026-05-21T03:51:05.413Z"
locales:
  - [en](https://longbridge.com/en/quote/VIRX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/VIRX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/VIRX.US/news.md)
---

# VIRX.US (VIRX.US) — Related News

### [Viatris Inc. Stock Falls Friday, Underperforms Market](https://longbridge.com/en/news/285776793.md)
*2026-05-08T21:09:43.000Z*
> Shares of Viatris Inc. (VTRS) fell 1.27% to $17.17 on Friday, underperforming the overall positive market, with the S&P 

### [Bioventix CFO Increases Personal Stake with Share Purchase](https://longbridge.com/en/news/281523432.md)
*2026-04-02T12:22:13.000Z*
> Bioventix CFO Increases Personal Stake with Share Purchase

### [ValiRx updates registered office as it advances oncology and women’s health focus](https://longbridge.com/en/news/281166944.md)
*2026-03-31T10:14:47.000Z*
> ValiRx updates registered office as it advances oncology and women’s health focus

### [Centivax Closes $37 Million Financing to Accelerate Phase 2 Clinical Development of Universal Flu and Advance Follow-On Portfolio to Clinical Readiness](https://longbridge.com/en/news/281030074.md)
*2026-03-30T13:13:14.000Z*
> On March 30, 2026, a biotechnology company named Centivax, Inc. based in South San Francisco completed a funding round t

### [ValiRx trims costs and expands oncology pipeline with new human and veterinary initiatives](https://longbridge.com/en/news/280581823.md)
*2026-03-26T07:20:20.000Z*
> ValiRx trims costs and expands oncology pipeline with new human and veterinary initiatives

### [Virewirx awarded $1.9M SBIR contract to develop advanced 5G system for OUSW to ensure mission-critical communications.](https://longbridge.com/en/news/276751637.md)
*2026-02-24T14:17:51.000Z*
> A company in San Diego, Virewirx, has received a Phase II Small Business Innovation Research (SBIR) OUSW (R&E) FutureG c

### [Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026](https://longbridge.com/en/news/276544957.md)
*2026-02-22T22:16:59.000Z*
> Virion Therapeutics announced at CROI 2026 that its novel immunotherapy, VRON-0200, demonstrated broad and sustained ant

### [Viracta Therapeutics closes NAVAL-1 trial and explores strategic options; Board of Directors initiates process to explore alternatives.](https://longbridge.com/en/news/227577757.md)
*2025-02-07T20:16:55.000Z*
> On December 26, 2024, a company called Viracta Therapeutics, Inc. (Nasdaq: VIRX), located in San Diego, revealed plans t

### [Viracta Therapeutics Announces Wind Down of Operations](https://longbridge.com/en/news/227278201.md)
*2025-02-05T23:02:45.000Z*
> SAN DIEGO, Feb. 05, 2025 ( GLOBE NEWSWIRE ) -- Viracta Therapeutics, Inc. ( Nasdaq: VIRX ) , a clinical-stage precision